Vignesh Packiam, MD, discusses strategies to manage intravesical therapy toxicity in NMIBC, improve treatment tolerability, and preserve bladder function.
|Podcasts|May 10, 2022
The urologist's role in dispelling men's health myths
Author(s)Urology Times staff
“I think it's really important to understand the role of prevention and early detection,” says Michael Lutz, MD.
Advertisement
In this episode, Urology Times® Assistant Managing Editor Ben Saylor spoke with Dr. Michael Lutz. He discusses common myths and misconceptions surrounding men’s health and the urologist’s role in dispelling them. Lutz is a partner in the Michigan Institute of Urology and president of the MIU Men’s Health Foundation.
Advertisement
Related to this article
Melissa Hadley Barrett discusses real-world outcomes and tolerability of intranasal vardenafil for men with persistent erectile dysfunction despite prior standard therapy.
Juan J. Andino, MD, MBA, discusses surgical decision-making in prolonged ischemic priapism and how ischemia duration affects erectile dysfunction risk and treatment timing.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Advertisement
Advertisement
Trending on Urology Times
1
How PSMA-PET shapes staging and recurrence workup in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
4
Engy Habashy, MD, on the role of androgens in GSM management
5